Metabolomic Nuclear Magnetic Resonance Studies at Presymptomatic and Symptomatic Stages of Huntington’s Disease on a Drosophila Model
- 3 September 2020
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Proteome Research
- Vol. 19 (10) , 4034-4045
Abstract
Huntington's disease (HD) is an inherited neurodegenerative disorder, for which diagnostic development and discovery of new therapeutic targets are urgently required. In this study, a model of HD in Drosophila melanogaster has been used to identify metabolic biomarkers at presymptomatic and symptomatic stages of the disease. The pan-neuronal expression of a pathogenic fragment of the human Huntingtin (HTT) protein containing a 93-repeat polyglutamine expansion (Httex1p Q93) in transgenic flies induces a neuropathology with several characteristics of the human disease. The discriminant metabolites between the diseased flies and their controls were identified by 1H-nuclear magnetic resonance (NMR) and orthogonal partial least squares discriminant multivariate analysis (OPLS-DA). The experiments carried out with 10-day-old flies allowed us to identify a set of 10 biomarkers of the presymptomatic stage: NAD+, AMP, fumarate, asparagine, dimethylamine, β-alanine, glutamine, succinate, glutamate and ethanol. Remarkably, the experiments conducted with 16-day-old flies, when the symptoms of the disease were present, highlighted a different set of 6 biomarkers: phosphocholine, ethanolamine, 2-oxoglutarate, succinate, pyruvate and acetate. Our results provide a better understanding of the metabolic impairments in a widely used HD model and demonstrate that metabolism perturbations change dramatically during the development of the disease.Keywords
Funding Information
- Centre National de la Recherche Scientifique
- Centre-Val de Loire region
This publication has 70 references indexed in Scilit:
- Brain metabolite alterations and cognitive dysfunction in early Huntington's diseaseMovement Disorders, 2012
- Cortical Metabolites as Biomarkers in the R6/2 Model of Huntington's DiseaseJournal of Cerebral Blood Flow & Metabolism, 2011
- Exploratory 7-Tesla magnetic resonance spectroscopy in Huntington’s disease provides in vivo evidence for impaired energy metabolismJournal of Neurology, 2011
- Metabolic Profiling of 3-Nitropropionic Acid Early-Stage Huntington’s Disease Rat Model Using Gas Chromatography Time-of-Flight Mass SpectrometryJournal of Proteome Research, 2011
- Energy deficit in Huntington disease: why it mattersJournal of Clinical Investigation, 2011
- Probing the Metabolic Aberrations Underlying Mutant Huntingtin Toxicity in Yeast and Assessing Their Degree of Preservation in Humans and MiceJournal of Proteome Research, 2009
- A Large Number of Protein Expression Changes Occur Early in Life and Precede Phenotype Onset in a Mouse Model for Huntington DiseaseMolecular & Cellular Proteomics, 2009
- Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington’s diseaseHuman Molecular Genetics, 2008
- BioMagResBankNucleic Acids Research, 2007
- Neurochemical changes in Huntington R6/2 mouse striatum detected by in vivo1H NMR spectroscopyJournal of Neurochemistry, 2006